| Date | Title | | | 05/09/13 | Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference| Live Audio Webcast Thursday, May 16, 2013
SAN DIEGO, May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
The live presentation takes place on Thursday, May 16 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time. The presentation will be webcast and may be accessed on the ... |
|  | | 05/02/13 | Neurocrine Biosciences Reports First Quarter 2013 Results| ELAGOLIX ENTERS PHASE IIB FOR UTERINE FIBROIDS, ENDOMETRIOSIS PHASE III PROGRAM ON TRACK
SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2013. For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a net loss of $0.9 million, or $0.01 loss per share, for the same period in 2012. This $11.2 million change in operating results is p... |
| | | 04/26/13 | Neurocrine Biosciences Announces Conference Call And Webcast To Present First Quarter 2013 Financial Results| Conference Call and Webcast Scheduled For Thursday, May 2, 2013
SAN DIEGO, April 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2013 financial results after the Nasdaq market closes on Thursday, May 2, 2013. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 2, 2013 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific T... |
| | | 04/24/13 | Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference| Live Audio Webcast Wednesday, May 1, 2013
SAN DIEGO, April 24, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Needham 12th Annual Healthcare Conference in New York City.
The live presentation takes place on Wednesday, May 1 at 9:20 a.m. Eastern Time / 6:20 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's ... |
| | | 03/27/13 | Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids| STUDY WILL EVALUATE SIX MONTHS OF TREATMENT IN 280 SUBJECTS
SAN DIEGO, March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine fibroids and endometriosis. Neurocrine and AbbVie entered into a collaboration and license agreement ... |
| | | 03/11/13 | Neurocrine Biosciences To Present At The 25th Annual Roth Conference| Live Audio Webcast Monday, March 18, 2013
SAN DIEGO, March 11, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Roth Conference in Laguna Niguel.
The live presentation takes place on Monday, March 18 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocr... |
| | | 02/27/13 | Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference| Live Audio Webcast Wednesday, March 6, 2013
SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 33rd Annual Health Care Conference in Boston.
The live presentation takes place on Wednesday, March 6 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's websit... |
| | | 02/08/13 | Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results| ANNOUNCES 2013 CLINICAL MILESTONES FOR RAPIDLY MATURING R&D PIPELINE
SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.
For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31... |
| | | 02/06/13 | Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013| Live Audio Webcast Wednesday, February 13, 2013
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Swann Global Healthcare Conference 2013 in New York City.
The live presentation takes place on Wednesday, February 13 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. The presentation will be webcast and may be accessed on the Company... |
| | | 02/01/13 | Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results| Conference Call and Webcast Scheduled For Friday, February 8, 2013
SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, February 8, 2013 a... |
| | | 01/23/13 | Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor| COMPLEMENTS COMPOSITION OF MATTER PATENT IN THE UNITED STATES
SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2) NBI-98854.
European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. This patent covers chemical compos... |
| |
|
